The second trial provides men with metastatic prostate cancer access to prostate-specific membrane antigen (PSMA)-targeted therapy prior to chemotherapy. Currently, PSMA-targeted therapy is only available after chemotherapy. However, phase III clinical trials have shown that PSMA-targeted therapies are more effective and have lower toxicities than chemotherapies for prostate cancer.
"The 177Lu-PNT2002 Expanded Access Protocol provides PSMA-targeted therapy earlier in the course of disease," said Dr. Ulaner. "We aim to enhance treatment options for patients with metastatic prostate cancer, while avoiding the side effects of chemotherapy.